Abstract
Administration of spironolactone in standard dosage to nine women with mild renal disease resulted in amenorrhea in six and marked menstrual irregularity in a seventh. Discontinuation of therapy resulted in normal menstrual periods within two months in every patient. The drug action causing this side effect may be responsible for previously reported gynecomastia, but this action is unknown. The high incidence of amenorrhea in this group may be due to increased drug susceptibility or decreased drug elimination in patients with kidney disease.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
